Literature DB >> 23682078

Identification of putative immunologic targets for colon cancer prevention based on conserved gene upregulation from preinvasive to malignant lesions.

Elizabeth K Broussard1, Rachel Kim, Jesse C Wiley, Juan Pablo Marquez, James E Annis, David Pritchard, Mary L Disis.   

Abstract

The length of time required for preinvasive adenoma to progress to carcinoma, the immunogenicity of colorectal cancer (CRC), and the identification of high-risk populations make development and testing of a prophylactic vaccine for the prevention of CRC possible. We hypothesized that genes upregulated in adenoma relative to normal tissue, which maintained increased expression in CRC, would encode proteins suitable as putative targets for immunoprevention. We evaluated existing adenoma and CRC microarray datasets and identified 160 genes that were ≥2-fold upregulated in both adenoma and CRC relative to normal colon tissue. We further identified 23 genes that showed protein overexpression in colon adenoma and CRC based on literature review. Silencing the most highly upregulated genes, CDH3, CLDN1, KRT23, and MMP7, in adenoma and CRC cell lines resulted in a significant decrease in viability (P < 0.0001) and proliferation (P < 0.0001) as compared to controls and an increase in cellular apoptosis (P < 0.05 for CDH3, KRT23). Results were duplicated across cell lines representing microsatellite instability, CpG island methylator, and chromosomal instability phenotypes, suggesting immunologic elimination of cells expressing these proteins could impact the progression of all CRC phenotypes. To determine whether these proteins were immunogens, we interrogated sera from early stage CRC patients and controls and found significantly elevated CDH3 (P = 0.006), KRT23 (P = 0.0007), and MMP7 (P < 0.0001) serum immunoglobulin G in cases as compared to controls. These data show a high throughput approach to the identification of biologically relevant putative immunologic targets for CRC and identified three candidates suitable for vaccine development. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23682078      PMCID: PMC3718634          DOI: 10.1158/1940-6207.CAPR-12-0484

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  50 in total

Review 1.  Molecular targets for cancer chemoprevention.

Authors:  William N William; John V Heymach; Edward S Kim; Scott M Lippman
Journal:  Nat Rev Drug Discov       Date:  2009-03       Impact factor: 84.694

2.  A new formula for predicting liver metastasis in patients with colorectal cancer: immunohistochemical analysis of a large series of 439 surgically resected cases.

Authors:  Hiroki Ochiai; Yukihiro Nakanishi; Yuri Fukasawa; Yasunori Sato; Kimio Yoshimura; Yoshihiro Moriya; Yae Kanai; Masahiko Watanabe; Hirotoshi Hasegawa; Yuko Kitagawa; Masaki Kitajima; Setsuo Hirohashi
Journal:  Oncology       Date:  2008-08-26       Impact factor: 2.935

3.  The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.

Authors:  Ajay Goel; Takeshi Nagasaka; Christian N Arnold; Toru Inoue; Cody Hamilton; Donna Niedzwiecki; Carolyn Compton; Robert J Mayer; Richard Goldberg; Monica M Bertagnolli; C Richard Boland
Journal:  Gastroenterology       Date:  2006-09-20       Impact factor: 22.682

4.  Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.

Authors:  Maria V Grau; Robert S Sandler; Gail McKeown-Eyssen; Robert S Bresalier; Robert W Haile; Elizabeth L Barry; Dennis J Ahnen; Jiang Gui; Robert W Summers; John A Baron
Journal:  J Natl Cancer Inst       Date:  2009-02-10       Impact factor: 13.506

5.  Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.

Authors:  John A Baron; Robert S Sandler; Robert S Bresalier; Angel Lanas; Dion G Morton; Robert Riddell; Erik R Iverson; David L Demets
Journal:  Lancet       Date:  2008-10-14       Impact factor: 79.321

6.  Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay.

Authors:  Jin C Kim; Dae D Kim; Yoo M Lee; Tae W Kim; Dong H Cho; Moon B Kim; Seong G Ro; Seon Y Kim; Yong S Kim; Jung S Lee
Journal:  Int J Colorectal Dis       Date:  2008-10-01       Impact factor: 2.571

Review 7.  Development of vaccines for high-risk ductal carcinoma in situ of the breast.

Authors:  Brian J Czerniecki; Robert E Roses; Gary K Koski
Journal:  Cancer Res       Date:  2007-07-15       Impact factor: 12.701

8.  Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine.

Authors:  Stefan K Burgdorf; Anders Fischer; Peter S Myschetzky; Signe B Munksgaard; Mai-Britt Zocca; Mogens H Claesson; Jacob Rosenberg
Journal:  Oncol Rep       Date:  2008-12       Impact factor: 3.906

9.  Ectopic expression of P-cadherin correlates with promoter hypomethylation early in colorectal carcinogenesis and enhanced intestinal crypt fission in vivo.

Authors:  Anita Milicic; Lea-Anne Harrison; Robert A Goodlad; Robert G Hardy; Anna M Nicholson; Michal Presz; Oliver Sieber; Sonia Santander; James H Pringle; Nikki Mandir; Philip East; Jolanta Obszynska; Scott Sanders; Elena Piazuelo; Jacqui Shaw; Rebecca Harrison; Ian P Tomlinson; Stuart A C McDonald; Nicholas A Wright; Janusz A Z Jankowski
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness.

Authors:  D G Molleví; A Aytes; L Padullés; M Martínez-Iniesta; N Baixeras; R Salazar; E Ramos; J Figueras; G Capella; A Villanueva
Journal:  Br J Cancer       Date:  2008-10-28       Impact factor: 7.640

View more
  17 in total

Review 1.  The dawn of vaccines for cancer prevention.

Authors:  Olivera J Finn
Journal:  Nat Rev Immunol       Date:  2017-12-27       Impact factor: 53.106

Review 2.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

3.  Identification of a 3-gene signature for predicting the prognosis of stage II colon cancer based on microsatellite status.

Authors:  Xiangxiong Huang; Heyang Xu; Yujie Zeng; Qiusheng Lan; Lu Liu; Wei Lai; Zhonghua Chu
Journal:  J Gastrointest Oncol       Date:  2021-12

4.  Transforming Cancer Prevention through Precision Medicine and Immune-oncology.

Authors:  Thomas W Kensler; Avrum Spira; Judy E Garber; Eva Szabo; J Jack Lee; Zigang Dong; Andrew J Dannenberg; William N Hait; Elizabeth Blackburn; Nancy E Davidson; Margaret Foti; Scott M Lippman
Journal:  Cancer Prev Res (Phila)       Date:  2016-01

Review 5.  Cancer immunoprevention.

Authors:  Olivera J Finn; Pamela L Beatty
Journal:  Curr Opin Immunol       Date:  2016-01-19       Impact factor: 7.486

Review 6.  Cancer immunoprevention--the next frontier.

Authors:  Marie-Anne D Smit; Elizabeth M Jaffee; Eric R Lutz
Journal:  Cancer Prev Res (Phila)       Date:  2014-09-22

7.  Gene-expression analysis of a colorectal cancer-specific discriminatory transcript set on formalin-fixed, paraffin-embedded (FFPE) tissue samples.

Authors:  Alexandra Kalmár; Barnabás Wichmann; Orsolya Galamb; Sándor Spisák; Kinga Tóth; Katalin Leiszter; Boye Schnack Nielsen; Barbara Kinga Barták; Zsolt Tulassay; Béla Molnár
Journal:  Diagn Pathol       Date:  2015-07-25       Impact factor: 2.644

8.  MiR-3960 binding sites with mRNA of human genes.

Authors:  Anatoly Ivashchenko; Olga Berillo; Anna Pyrkova; Raigul Niyazova; Shara Atambayeva
Journal:  Bioinformation       Date:  2014-07-22

9.  Meta-analysis of possible role of cadherin gene methylation in evolution and prognosis of hepatocellular carcinoma with a PRISMA guideline.

Authors:  Chunxiao Zhu; Xuefeng Feng; Guoliang Ye; Tao Huang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

Review 10.  Colorectal cancer prevention: Immune modulation taking the stage.

Authors:  Rochelle Fletcher; Yi-Jun Wang; Robert E Schoen; Olivera J Finn; Jian Yu; Lin Zhang
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2018-01-31       Impact factor: 11.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.